Aalborg University Hospital
Aalborg, 9000, Denmark
NCT Number: NCT06385561
Tramadol is a weak opioid and widely used to treat moderate to severe pain. Stronger opioids are known to inhibit gastrointestinal motility and secretion, however the effects of tramadol on gastrointestinal function remains less understood. The aim of this study was to determine to what degree tramadol causes opioid-induced bowel dysfunction by using an objective design to explore gastrointestinal transit, motility pattern, secretion, and colonic volume, in a group of healthy male volunteers.
Looking for future studies?
Notify Me20 year–40 year
Male
Interventional
Phase 2
Aalborg, 9000, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)
Placebo is administered orally twice daily.
Time frame: From day 4 to day 8
Difference in hours from ingestion of a 3D Transit Capsule to expulsion of the capsule during active and placebo treatment
Time frame: From day 4 to day 8
Difference in hours from the entering in the colon of a 3D Transit Capsule to expulsion of the capsule during active and placebo treatment
Time frame: From day 1 to day 10
Measured on the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire (ranging from 0 (symptom absent) to 4 (very severe).
Time frame: From day 1 to day 10
Number of spontaneous bowel movements per day
Time frame: From day 1 to day 10
Rated on the Bristol Stool Form Scale (ranging from type 1 (constipation) - type 7 (diarrhea))
Time frame: Day 1 and day 10
Measured on the Gastrointestinal Symptom Rating Score (GSRS) questionnaire (ranging from 0 (no discomfort) to 6 (very severe discomfort)
Time frame: Day 1 and day 10
Measured by the Bowel Function Index (BFI) questionnaire (ranging from 0 (not at all) to 100 (very strong).
Time frame: Day 10
Assessed using the Rome IV C6 criteria consisting of 7 items rated as either true or false. 2 or more items rated as "true" indicates functional constipation
Time frame: From day 4 to day 8
Number of motility patterns in the colon measured by the 3D Transit Capsule
Time frame: Day 13, 14 or 15
Measured by the Subjective Opiate Withdrawal Scale (ranging from 0 (not at all) to 4 /extremely)
Time frame: Day 10
Volumetric quantification of the colon measured using T2-weighted MRI images
Time frame: Day 10
Analysis of colonic water content measured using heavily T2-weighted MRI images
Time frame: Day 1 and day 10
Analysis of gastric half emptying time after ingestion of a standardized meal measured by MRI
Time frame: Day 1 and day 10
Analysis of gastric contraction amplitude after ingestion of a standardized meal measured by MRI
Time frame: Day 1 and day 10
Analysis of gastric contraction frequency after ingestion of a standardized meal measured by MRI
Time frame: Day 1 and day 10
Analysis of small bowel motility after ingestion of a standardized meal measured using dynamic MRI images. A semi-automated analysis software enables registration of small bowel motility with the calculation of regional motility maps and quantification of motility indices.
Time frame: Day 1 and day 10
Analysis of small bowel water content measured using heavily T2-weighted MRI images
Asbjørn Mohr Drewes
Other
The Influence of Tramadol on Opioid-induced Bowel Dysfunction - An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled, Cross-over Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01298219
Chemically-Induced Disorders, Constipation
Athens, Alabama, United States
View Trial DetailsNCT00620061
Chemically-Induced Disorders, Constipation
Birmingham, Alabama, United States
View Trial DetailsNCT00595946
Chemically-Induced Disorders, Constipation
Birmingham, Alabama, United States
View Trial DetailsNCT00597428
Chemically-Induced Disorders, Constipation
Tuscaloosa, Alabama, United States
View Trial Details